Table 2.

Demographics and baseline disease characteristics of study population

	No TNF use (Group 1)	TNF use pre PCa diagnosis (Group 2)	p Value
Number	119814	390
Age at Dx [mean(SD)]	65.76 (8.14)	64.96 (6.85)	0.052
Less than 55	8379 (7.0%)	20 (5.1%)	0.179
55–64	49546 (41.4%)	174 (44.6%)	0.21
65–74	43316 (36.2%)	159 (40.8%)	0.066
75 and Up	18573 (15.5%)	37 (9.5%)	0.001
Race			< 0.001
African American	32655 (27.3%)	56 (14.4%)
White	82894 (69.2%)	323 (82.8%)
Other	1318 (1.1%)	6 (1.5%)
Unknown	2947 (2.5%)	5 (1.3%)
T Stage 1	78899 (65.9%)	286 (73.3%)	0.002
T Stage 2	36839 (30.7%)	98 (25.1%)	0.019
T Stage 3 or 4	4075 (3.4%)	6 (1.5%)	0.059
Gleason 6	48261 (40.3%)	172 (44.1%)	0.138
Gleason 7	47878 (40.0%)	162 (41.5%)	0.56
Gleason 8 or Higher	23690 (19.8%)	56 (14.4%)	0.009
Mean pre diagnostic PSA (SD)	18.15 (71.59)	8.60 (11.99)	0.011
Median pre diagnostic PSA	6.55	5.5
PSA over 20 at Dx	12253 (11.4%)	23 (6.3%)	0.003
N Stage 1	1965 (1.6%)	6 (1.5%)	1
M Stage 1	4840 (4.0%)	9 (2.3%)	0.108

TNF tumor necrosis factor, Dx Diagnosis, SD standard deviation, PSA prostate specific antigen